PT  - JOURNAL ARTICLE
AU  - Puzi Jiang
AU  - Sicheng Wu
AU  - Qibin Luo
AU  - Xing-ming Zhao
AU  - Wei-Hua Chen
TI  - Metagenomic analysis of common intestinal diseases reveals relationships among microbial signatures and powers multi-disease diagnostic models
AID  - 10.1101/19013136
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 19013136
4099  - http://medrxiv.org/content/early/2021/01/29/19013136.short
4100  - http://medrxiv.org/content/early/2021/01/29/19013136.full
AB  - Common intestinal diseases such as Crohn’s disease (CD), ulcerative colitis (UC) and colorectal cancer (CRC), share clinical symptoms and altered gut microbes, necessitating cross-disease comparisons and the use of multi-disease models. Here, we performed meta-analyses on thirteen fecal metagenome datasets of the three diseases. We identified 87 species and 65 pathway markers that were consistently changed in multiple datasets of the same diseases. According to their overall trends, we grouped the disease-enriched marker species into disease-specific and -common clusters, and revealed their distinct phylogenetic relationships: species in CD-specific cluster are phylogenetically related, while those in CRC-specific cluster are more distant; strikingly, UC-specific species are phylogenetically closer to CRC, likely because UC-patients have higher risk of CRC. Consistent to their phylogenetic relationships, marker species had similar within-cluster and different between-cluster metabolic preferences. There were part of marker species and pathways correlated with an indicator of leaky gut, suggesting a link between gut dysbiosis and human derived contents. Marker species showed more coordinated changes and tighter inner-connections in cases than the controls, suggesting that the diseased gut may represent a stressed environment and pose stronger selection to gut microbes. With the marker species and pathways, we constructed four high-performance (including multi-disease) models with AUROC of 0.87 and true positive rates up to 90%, and explained their putative clinical applications. We identified consistent microbial alterations in common intestinal diseases, revealed metabolic capacities and the relationships among marker bacteria in distinct states, and supported the feasibility of metagenome-derived multi-disease diagnosis.Importance Gut microbes have been identified as potential markers in distinguishing patients from controls in colorectal cancer, ulcerative colitis and Crohn’s disease individually, whereas there lacks a systematic analysis to investigate the exclusive microbial shifts of these enteropathies with similar clinical symptoms. Our meta-analysis and cross-disease comparisons identified consistent microbial alterations in each enteropathy, revealed microbial ecosystems among marker bacteria in distinct states, and demonstrated the necessity and feasibility of metagenome-based multi-disease classifications. To the best of our knowledge, this is the first study that constructed multi-class models in these common intestinal diseases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was partly supported by National Key Research and Development Program of China [2019YFA0905600 to W.H.C.], National Natural Science Foundation of China [61932008, 61772368, 61572363 to X.M.Z], National Key R&D Program of China [2018YFC0910500 to X.M.Z], Natural Science Foundation of Shanghai [17ZR1445600 to X.M.Z], Shanghai Municipal Science and Technology Major Project [2018SHZDZX01 to X.M.Z] and ZJLab. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated and R codes during this study are available at https://github.com/whchenlab/2019-puzi-multi-gut-disease-classifier. Correspondence and requests for materials should be addressed to W.H.C. and X.M.Z... https://github.com/whchenlab/2019-puzi-multi-gut-disease-classifier